Trial Profile
A clinical trial of ANYARA in combination with an immunostimulating PD-1 inhibitor
Status:
Planning
Phase of Trial:
Phase I
Latest Information Update: 16 Feb 2018
Price :
$35
*
At a glance
- Drugs Naptumomab estafenatox (Primary)
- Indications Cancer
- Focus Adverse reactions
- 16 Feb 2018 New trial record
- 15 Feb 2018 According to an Active Biotech media release, this trial is expected to initiate during the second half of 2018.